 |
Ranbaxy was fined $500 million by the US Food and Drug Administration (USFDA) for making and selling adulterated drugs". |
Forbes India Magazine - Daiichi could be the biggest beneficiary of the Sun Pharma-Ranbaxy deal: "India’s Sun Pharma, headed by billionaire Dilip Shanghvi, announced its decision to acquire the troubled and scandal ridden ' Ranbaxy Laboratories' from Japanese owners Daiichi Sankyo, in all-share deal valued at $3.2 billion.
Sun Pharma is the biggest winner in this deal, as Ranbaxy still controls 21% in the domestic The combined entity—the world’s fifth largest generic drug firm—will be more diversified with United States, Rest of the World and India contributing 47 percent, 31 percent and 22 percent of sales, respectively, initial analyst estimates reveal."
'Japan’s Daiichi acquired Ranbaxy from Malvinder and Shivinder Singh in 2008,who held the reins from her father " Mohan Singh with the belief that its dominance in cheap generic medicines would boost the Japanese firm’s revenues
The firm, started by Bhai Mohan Singh in 1961, after taking it over from two Amritsar-based cousins a decade earlier, was once India’s largest manufacturer of antibiotics in the 1980s.
In the entire scsheme of things ,Daiichi stands to be the biggest beneficiary from the new deal by letting go of Ranbaxy ownership.Itis waging a constantly legal battles It suffered losses for its Ranbaxy investment and failed to fully unlock Ranbaxy’s value.
ليست هناك تعليقات:
إرسال تعليق